Leading Edge Genomic Services & Solutions

About

Novogene Receives CAP accreditation for its Med NGS Clinical Lab in Tianjin, China

TIANJIN, CHINA – March 19, 2019 – Novogene, a leading provider of genomic services and solutions, announced today that the Tianjin Novogene Med Lab – NGS Clinical Lab for genomic testing has successfully renewed its CAP accreditation, passing rigorous on-site inspection by experts from the College of American Pathologists (CAP) in recognition of the high standards of excellence established since its first accreditation in February 2017.

The College of American Pathologists is a US non-governmental organization that is widely considered the leader in laboratory quality assurance. Based on standards and guidance from the Clinical & Laboratory Standards Institute (CLSI) and the Clinical Laboratory Improvement Amendments (CLIA) of 1988, the CAP has created detailed checklists containing a core set of requirements which apply to all areas performing laboratory tests and procedures. Through its laboratory quality solutions programs, the CAP improves patient safety and advances the quality of pathology and laboratory service through education, standard setting and ensuring laboratories meet or exceed regulatory requirements.

Founded on June 23rd, 2014, the Tianjin Novogene Med Lab – NGS Clinical Lab is a modern, large-scale and independent clinical laboratory established in accordance with the standards of provincial medical inspection institutes issued by the Ministry of Health in China. It was approved by the Municipal Health and Family Planning Commission in December 2014 for the application of clinical gene amplification technology. Since March 7th, 2016, the Med Lab has been operating according to the international authoritative clinical laboratory quality certification system-the CAP -and passed the professional on-site inspection by CAP experts on February 10th, 2017, making it the first CAP-accredited NGS clinical lab in mainland China. After two years of effective operation and continuous improvement of its quality system, the Tianjin Novogene Med Lab – NGS Clinical Lab has once again passed the on-site inspection and successfully maintained its CAP accreditation.

“With the renewal of our CAP accreditation, Novogene continues to be globally recognized as a high-quality clinical service provider,” said Dr. Jeff Cheng, Chief Scientific Officer and Global Head of BioPharmaceutical Services at Novogene. “We strive to offer our clients best-in-class genomic solutions to advance research in human health.”

Novogene’s continuing accreditation signals that the lab has achieved universally accepted benchmarks for the standardization and accuracy of its quality management system, experimental technique level, bioinformatics analyses and clinical interpretation ability. This achievement is an important milestone in further establishing Novogene as a leading global provider of genomic services and solutions.

About Novogene
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. With 1,800 employees, multiple branches around the world, 49 NGS-related patents, as well as over 950 publications in top-tier journals such as Nature and Science, the company has rapidly become a world leader in NGS services.